RxDoctor Payments Data

Lindsey Stenshoel

Family · Boise, IDNPI 1902185168

Payments from drug & device makers

$2,235in general payments, 2019–2025

Across 99 payments — averaging $22.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$698
  • AbbVie$353
  • E.r. Squibb & Sons, L.L.C.$326
  • Alkermes, Inc.$229
  • Teva Pharmaceuticals USA, Inc.$215
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$107
  • plus $308 from 9 others

What the payments were for

  • Food & beverage$2,06192%
  • Education$1748%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,235 in reported general payments places this provider in the 85th percentile of 809 family providers in Idaho.

See all family providers in Idaho

Medicare billing

Part B allowed, 2024
$39,861
Medicare patients
74
Services billed
491

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega TrinzaPaliperidone Palmitate26$264,748
Invega SustennaPaliperidone Palmitate57$205,396
IngrezzaValbenazine Tosylate24$192,152
AustedoDeutetrabenazine12$181,324
VraylarCariprazine Hcl110$161,067
Abilify AsimtufiiAripiprazole22$127,440
Paliperidone ErPaliperidone108$73,836
RexultiBrexpiprazole27$43,314
Aripiprazole182$23,486
Quetiapine Fumarate ErQuetiapine Fumarate66$15,401
BelsomraSuvorexant20$12,557
Clomipramine Hcl29$12,017
DayvigoLemborexant33$11,479
Olanzapine193$11,218
Clozapine168$10,638

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Trinza, Invega Sustenna$58$470,14483 claims
Neurocrine Biosciences, Inc.Ingrezza$698$192,15224 claims
Teva Pharmaceuticals USA, Inc.Austedo$215$181,32412 claims
Otsuka America Pharmaceutical, Inc.Abilify Asimtufii, Rexulti$70$170,75449 claims
AbbVieVraylar$353$161,067110 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 809 family providers in Idaho.

Other family in Boise

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →